Literature DB >> 12975592

Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery.

János Pataricza1, Irén Krassói, József Höhn, Attila Kun, Julius Gyula Papp.   

Abstract

Levosimendan, a new type of inodilator drugs, is known to activate membrane adenosine 3',5'-triphosphate-sensitive potassium (KATP) channels in some vascular smooth muscles and causes vasorelaxation. The involvement of potassium channels in the mechanism of the coronary artery relaxing effect of the drug has not been established. In the present study performed in the porcine epicardial coronary artery, the effect of levosimendan (0.009-3.2 microM) was compared to cromakalim (0.0125-5 microM), the known activator of ATP-sensitive potassium (KATP) channels, in the presence of glibenclamide (GLI), an inhibitor of KATP channels and tetraethylammonium (TEA), the non-selective inhibitor of potassium channels. The interaction of levosimendan with the specific calcium-activated potassium channel (KCa) blocker, iberiotoxin (IBTX), and the voltage-sensitive potassium channel (KV) blocker, 4-aminopyridine (4-AP), was also studied. All the experiments were performed in the isometric tension of endothelium denuded porcine isolated epicardial coronary arteries precontracted with 20 mM potassium chloride. 1 microM GLI decreased the maximum of cromakalim-induced relaxation by 60% but did not affect the action of levosimendan. In contrast, 2 mM TEA decreased only the coronary artery relaxing effect of levosimendan. 100 nM IBTX suppressed the maximum effect of levosimendan by only 15% while 0.5 mM 4-AP significantly shifted the concentration-response curve of the inodilator to the right. 5 mM 4-AP caused a maximum of 33% decrease of levosimendan-induced relaxation. These results indicate that, in porcine isolated epicardial coronary artery, the vasorelaxing mechanism of levosimendan involves the activation of voltage-sensitive and, at large concentrations, calcium-activated potassium channels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975592     DOI: 10.1023/a:1025331617233

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  12 in total

1.  The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Authors:  Nóra Erdei; Zoltán Papp; Piero Pollesello; István Edes; Zsolt Bagi
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

Review 2.  Future pharmacologic agents for treatment of heart failure in children.

Authors:  Brady S Moffett; Anthony C Chang
Journal:  Pediatr Cardiol       Date:  2006-08-23       Impact factor: 1.655

3.  Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.

Authors:  Ildikó Gödény; Piero Pollesello; István Edes; Zoltán Papp; Zsolt Bagi
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

4.  Levosimendan attenuates pulmonary vascular remodeling.

Authors:  M Revermann; M Schloss; A Mieth; A Babelova; K Schröder; S Neofitidou; J Buerkl; T Kirschning; R T Schermuly; C Hofstetter; R P Brandes
Journal:  Intensive Care Med       Date:  2011-05-31       Impact factor: 17.440

5.  Levosimendan and severe pulmonary hypertension during open heart surgery.

Authors:  Ferit Cicekcioglu; Ali Ihsan Parlar; Ozgur Ersoy; Kerem Yay; Alaa Hijazi; S Fehmi Katircioglu
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-11-12

6.  Levosimendan Relaxes Pulmonary Arteries and Veins in Precision-Cut Lung Slices - The Role of KATP-Channels, cAMP and cGMP.

Authors:  Annette D Rieg; Rolf Rossaint; Eva Verjans; Nina A Maihöfer; Stefan Uhlig; Christian Martin
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

7.  Levosimendan Improves Oxidative Balance in Cardiogenic Shock/Low Cardiac Output Patients.

Authors:  Elena Grossini; Serena Farruggio; Daniele Pierelli; Virginia Bolzani; Lidia Rossi; Piero Pollesello; Carolina Monaco
Journal:  J Clin Med       Date:  2020-01-30       Impact factor: 4.241

Review 8.  Evidence based review of management of cardiorenal syndrome type 1.

Authors:  Leong Tung Ong
Journal:  World J Methodol       Date:  2021-07-20

9.  Levosimendan Administration in Limb Ischemia: Multicomponent Signaling Serving Kidney Protection.

Authors:  Peter Onody; Peter Aranyi; Zsolt Turoczi; Rita Stangl; Andras Fulop; Emese Dudas; Gabor Lotz; Attila Szijarto
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

Review 10.  Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

Authors:  Antoine Herpain; Stefaan Bouchez; Massimo Girardis; Fabio Guarracino; Johann Knotzer; Bruno Levy; Tobias Liebregts; Piero Pollesello; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Fabio Sangalli
Journal:  J Cardiovasc Pharmacol       Date:  2019-01       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.